PM

Philip Morris International’s moat is built on global scale, pricing power in combustibles, and a fast-growing smoke-free portfolio led by IQOS heated tobacco and ZYN nicotine pouches. In 2025, smoke-free products reached 41.5% of net revenues (about $17B), reinforcing that PMI is increasingly competing on innovation and brand equity rather than only cigarette share. The expanded Ferrari partnership is marketing-heavy, but it fits PMI’s strategy of premiumizing and accelerating conversion to smoke-free platforms.

Financial execution improved materially in 2025: reported diluted EPS was $7.26 and adjusted diluted EPS was $7.54, with adjusted operating margin around 40% and organic revenue growth of about 6.5%. For 2026, PMI guided to organic net revenue growth of 5–7% and adjusted EPS of $8.09–$8.54, implying another year of solid earnings momentum but with known headwinds (notably Japan heated-tobacco excise increases in April and October 2026). Valuation looks demanding versus staples peers at roughly 29x trailing earnings, though the dividend remains attractive at about $1.47 quarterly (around $5.88 annualized, ~3.5%–3.7% yield).

Over the next 12 months, the thesis centers on continued ZYN supply/volume growth and sustained IQOS expansion offsetting predictable combustible declines, with guidance delivery as the key proof point. Catalysts include the April 22, 2026 earnings report and any tightening/raising of 2026 EPS ranges, plus further evidence that smoke-free mix is lifting margins. Key risks are regulatory/tax actions (especially heated tobacco), any U.S. nicotine pouch demand slowdown, and multiple compression if rates stay higher.

Recommendation: HOLD. PMI offers credible smoke-free-led growth and a durable dividend, but the stock already prices in a lot of that progress at a high multiple, leaving less room for error versus near-term tax and regulatory volatility.